Withus Pharmaceutical위더스제약
330350 · KOSDAQ · ₩330350 · 위더스제약
₩6,370▲ ₩10 (0.16%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 64.4% | 64.7% | 63.8% | 60.7% | 59.3% | 58.4% |
| Operating margin | 3.6% | 5.3% | 5.5% | 9.9% | 7.5% | 8.5% |
| Net margin | 5.0% | 4.7% | 4.7% | 9.9% | 3.8% | 7.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +5.0% | +3.6% | +28.2% | +23.9% | +12.6% | — |
| Operating income growth | −28.1% | 0.0% | −28.4% | +62.2% | −0.2% | — |
| Net income growth | +13.5% | +3.8% | −39.9% | +221.0% | −41.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 5.6% | 5.2% | 5.2% | 9.2% | 3.0% | 5.3% |
| Return on assets | 4.0% | 3.7% | 3.6% | 6.4% | 2.1% | 3.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 38.6% | 39.4% | 44.6% | 44.9% | 43.8% | 47.1% |
| Net debt to equity | −1.6% | −0.1% | 5.1% | 10.2% | 14.6% | 9.9% |
| Current ratio | 204.5% | 206.2% | 180.2% | 187.8% | 232.5% | 318.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Withus Pharmaceutical / 위더스제약 / 330350 / KRX:330350
Source: KRX statistical information